FDA releases draft guidance on assessment of PROs for cancer trials
Regulatory NewsJoanne S. Eglovitch
Clinical TrialsNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyRegulatory NewsJoanne S. EglovitchClinical TrialsNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy